ASX 200

Two stocks make up 22% of the ASX. Here’s why some investors are rethinking “diversified” portfolios.

Real income in an inflationary world: why listed real assets may offer the pricing power your portfolio needs.

Follow up to "Australia’s lazy investment strategy is finally dead" Readers demanded a Structured Investments explainer, here it is!

Over the past decade they’ve become globally significant E&Ps. Their costs have fallen and productivity’s risen – and match ExxonMobil’s.

Global X reveals the ASX’s greatest wealth creators over the past decade. Did a bank or miner come out on top? Check out the awesome data.

IML's Marc Whittaker sees the GFC-level valuation gap in small caps as a rare chance to buy quality at the right price.

Andrew Wielandt explains how he's positioning client portfolios across different risk profiles in a world that feels topsy-turvy.

One upshot of the much-discussed market dislocation is that great companies are back at prices where they represent good value.

Marking the banks post the May 2026 reporting season

A look at Australia’s best-performing growth funds over five years, and the return drivers behind the leaders.

Tax policy no longer subsidises mediocre returns and lazy strategy and replacing them will be a positive change for smart investors

Australian shares remain 'tricky' as profit warnings continue to be issued, but in the background AI beneficiaries are making a come-back

As the big banks hit record highs, the experts reveal where they're hunting for value in ASX financials.

Seneca’s Luke Laretive explains what separates genuine 10-baggers from market hype, and why patience matters most.

As AI drives power demand, hear Jason explore the energy war, semiconductors, P.Credit, geopolitics, CCY, capital flows & where to allocate.

ASX Defence vs global primes: Tech cohort at a premium, yet growth unearned; Services at a discount, despite sovereign-backed contracts.

Dispersions in valuations both locally and globally represent great opportunities for investors with the conviction to take a position.

The reset has created winners and losers. From small caps to global leaders, four experts share where they see value emerging in healthcare.

Two small & mid-cap gurus face off on fallen angels and high-flyers. Plus: Key insights from the Macquarie Conference.

Relying on the investment playbook of the 2010s may no longer cut it.

The Macquarie Conference has become one of the must-attend events in every Australian fund manager’s diary. In this podcast IML portfolio managers Daniel Moore and...

NextDC’s recent subordinated note issuance highlights a recurring challenge for credit investors: exposure to equity‑like risk without commensurate return. While the...

Julia Weng (Paradice) and Hamish FitzSimons (AllianceBernstein) diagnose ASX healthcare's brutal year and name the stocks set for recovery

Pricing tailwinds, AI infrastructure and a catch-up trade: where this small-cap investor sees opportunity now.